ARCHIVES

Modality Combo Decreases Prostate Cancer Recurrence

This article is from The Cancer Letter archive.

Vol. 27 No. 8 | August 27, 2004

Download PDF Visit The Full Archive

Related Articles

FDA Proposal On Dissemination of Off-Label Drug Information Doesn’t Go Far Enough, Cancer Groups Say

January 26, 1996

NIEHS Conference to Look At 21st Century Issues

April 1, 1988

Prostatic Cancer Workshop Reports On Etiology, Diagnosis, Treatment

September 10, 1976

NCI plans 11-16 percent budget cuts in new grants to maintain R01 payline at 20th percentile.

November 28, 2003

R01 and P01 Grants Will No Longer Support Phase III Clinical Trials

July 25, 2013

FDA Accepts Advisory Committee’s Recommendations On NDA, Labeling

October 26, 1979